TAMIFLU 30 MG

Šalis: Izraelis

kalba: anglų

Šaltinis: Ministry of Health

Veiklioji medžiaga:

OSELTAMIVIR AS PHOSPHATE

Prieinama:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

ATC kodas:

J05AH02

Vaisto forma:

CAPSULES

Sudėtis:

OSELTAMIVIR AS PHOSPHATE 30 MG

Vartojimo būdas:

PER OS

Recepto tipas:

Required

Pagaminta:

HOFFMANN LA ROCHE LTD, SWITZERLAND

Gydymo sritis:

OSELTAMIVIR

Terapinės indikacijos:

Treatment of influenza : Treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. Prophylaxis of influenza : Post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.משטר מינון 10/2/2019

Leidimo data:

2014-09-22

Pakuotės lapelis

BODY WEIGHT
RECOMMENDED
DOSAGE FOR
10 DAYS OF
TREATMENT*
WHICH CAPSULE SHOULD
BE TAKEN?
Less or equal
to 15 kg
30 mg
once daily
1 capsule of 30 mg
once daily
More than 15 kg
up to 23 kg
45 mg
once daily
1 capsule of 45 mg
once daily
More than 23 kg
up to 40 kg
60 mg
once daily
2 capsules of 30 mg
once daily
More than 40 kg
75 mg
once daily
1 capsule of 75 mg or
1 capsule of 30 mg
+ 1 capsule of 45 mg
once daily
* In the event of an outbreak of influenza in the community,
preventive treatment with TAMIFLU can be taken for a period of up
to 6 weeks. Consult your attending doctor regarding for how long
the medicine should be taken.
ADULTS (FROM 13 YEARS OF AGE AND ABOVE):
∙ TREATMENT
Start treatment immediately upon the first appearance of influenza
symptoms (up to 48 hours). The recommended dosage is 75 mg
TAMIFLU twice daily for 5 days.
∙ PREVENTION
Start preventive treatment immediately after exposure to the
disease and/or as soon as you suspect you have been infected.
The recommended dosage is 75 mg TAMIFLU once daily. The doctor
will recommend the length of time that the medicine has to be
taken for. Generally, when taking preventive treatment after close
contact with a person with influenza, the recommended length of
time will be at least 10 days.
In the event of an outbreak of influenza in the community, preventive
treatment with TAMIFLU can be taken for up to 6 weeks
.
In patients suffering from kidney insufficiency (Creatinine clearance
10-60 mL/min), the dosages have to be adjusted.
During treatment with TAMIFLU, if there is no improvement in the
influenza symptoms or there is a deterioration or development of
new symptoms, consult the attending doctor.
Do not exceed the recommended dosage.
Swallow the medicine with water.
In special circumstances and only with the instruction of your doctor
or pharmacist:
The capsule can be opened and its entire contents swallowed in
the following way:
∙ Take the required dose of TAMIFLU capsules: 30, 45, 60 or 75 mg.
∙ Open the capsule carefully and pour the comp

Prekės savybės

טמרופ
ןולע
הז
עבקנ
ע
"
י
דרשמ
תואירבה
ונכותו
קדבנ
רשואו
לע
ודי
ב טסוגוא
2015
1
TAMIFLU
®
r
Oseltamivir
CAPSULES
1
INDICATIONS AND USAGE
TREATMENT OF INFLUENZA
:
The treatment of uncomplicated acute illness due to influenza
infection in adults and children 1 year of age or
older (30mg and 45 mg) who have been symptomatic for no more than 2
days.
PROPHYLAXIS OF INFLUENZA
:
-
Post exposure prevention in adults and children 1 year of age or older
following contact with a clinically
diagnosed influenza case when influenza virus is circulating in the
community.
-
The appropriate use of Tamiflu for prevention of influenza should be
determined on a case by case basis by
the circumstances and the population requiring protection. In
exceptional situations (e.g. in case of a
mismatch between the circulating and vaccine virus strains, and a
pandemic situation) seasonal prevention
could be considered in adults and children 1 year of age or older.
TAMIFLU CAPSULES 75 MG is indicated for patients who weight > 40 k
body weight.
LIMITATIONS OF USE
The following points should be considered before initiating treatment
or prophylaxis with TAMIFLU:
-
Efficacy of TAMIFLU in patients who begin treatment after 48 hours of
symptoms has not been established.
-
TAMIFLU is not a substitute for early influenza vaccination on an
annual basis as recommended by the
MOH (Ministry of Health).
-
There is no evidence for efficacy of TAMIFLU in any illness caused by
agents other than influenza viruses
types A and B.
-
Influenza viruses change over time. Emergence of resistance mutations
could decrease drug effectiveness.
Other factors (for example, changes in viral virulence) might also
diminish clinical benefit of antiviral
drugs. Prescribers should consider available information on influenza
drug susceptibility patterns and
treatment effects when deciding whether to use TAMIFLU.
2
DOSAGE AND ADMINISTRATION
2.1
DOSING FOR TREATMENT AND PROPHYLAXIS OF INFLUENZA
Treatment should begin within 2 d